Benjamin Djulbegovic

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. pmc New treatments compared to established treatments in randomized trials
    Benjamin Djulbegovic
    USF Clinical Translational Science Institute, Dpts of Medicine, Hematology and Health Outcome Research, USF and H LeeMoffitt Cancer Center, USF Health Clinical Research, University of South Florida, Tampa, Florida, USA
    Cochrane Database Syst Rev 10:MR000024. 2012
  2. pmc When should potentially false research findings be considered acceptable?
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, United States of America
    PLoS Med 4:e26. 2007
  3. doi Multiple myeloma: detecting the effects of new treatments
    Benjamin Djulbegovic
    Division of Hematologic Malignancies, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Lancet 371:1642-4. 2008
  4. pmc Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center, 12902 Magnolia Dr, MRC, Room 2067H, Tampa, FL 33612, USA
    Arch Intern Med 168:632-42. 2008
  5. doi Bisphosphonates in multiple myeloma: a network meta-analysis
    Rahul Mhaskar
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, USA
    Cochrane Database Syst Rev 5:CD003188. 2012
  6. doi Sequence of novel agents in multiple myeloma: an instrumental variable analysis
    Rachid Baz
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Leuk Res 37:1077-82. 2013
  7. pmc Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials
    Benjamin Djulbegovic
    Center for Evidence based medicine and Health Outcomes Research, Tampa, Florida, USA
    PLoS ONE 8:e58711. 2013
  8. ncbi Management of multiple myeloma: a systematic review and critical appraisal of published studies
    Ambuj Kumar
    Interdisciplinary Oncology Program of the H Lee Moffitt Cancer and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Lancet Oncol 4:293-304. 2003
  9. doi Towards a classification model to identify hospice candidates in terminally ill patients
    Eleazar Gil-Herrera
    Department of Industrial and Management System Engineering, University of South Florida, Tampa, FL 33620, USA
    Conf Proc IEEE Eng Med Biol Soc 2012:1278-81. 2012
  10. doi Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error
    Branko Miladinovic
    Center for Evidence based medicine and Health Outcomes Research, Department of Internal Medicine, Clinical and Translational Science Institute, Morsani College of Medicine, University of South Florida, 3515 East Fletcher Avenue, MDC 27, Tampa, FL 33612, USA
    J Clin Epidemiol 66:654-9. 2013

Research Grants

  1. Equipoise and the research integrity of clinical trials
    Benjamin Djulbegovic; Fiscal Year: 2002
  2. Blood vs. bone marrow stem transplant
    Benjamin Djulbegovic; Fiscal Year: 2003
  3. Evaluation of the Quality of Clinical Trials
    Benjamin Djulbegovic; Fiscal Year: 2005
  4. Treatment Success and Ethical Principle of Equipoise
    Benjamin Djulbegovic; Fiscal Year: 2010

Detail Information

Publications91

  1. pmc New treatments compared to established treatments in randomized trials
    Benjamin Djulbegovic
    USF Clinical Translational Science Institute, Dpts of Medicine, Hematology and Health Outcome Research, USF and H LeeMoffitt Cancer Center, USF Health Clinical Research, University of South Florida, Tampa, Florida, USA
    Cochrane Database Syst Rev 10:MR000024. 2012
    ..We investigated how often new, experimental treatments evaluated in randomized controlled trials (RCTs) are superior to established treatments...
  2. pmc When should potentially false research findings be considered acceptable?
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, United States of America
    PLoS Med 4:e26. 2007
    ..e., when should we accept early findings from a clinical trial indicating the benefits as true?). Obtaining absolute "truth" in research is impossible, and so society has to decide when less-than-perfect results may become acceptable...
  3. doi Multiple myeloma: detecting the effects of new treatments
    Benjamin Djulbegovic
    Division of Hematologic Malignancies, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Lancet 371:1642-4. 2008
  4. pmc Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center, 12902 Magnolia Dr, MRC, Room 2067H, Tampa, FL 33612, USA
    Arch Intern Med 168:632-42. 2008
    ..We assessed how often experimental cancer treatments that undergo testing in randomized clinical trials (RCTs) result in discovery of successful new interventions...
  5. doi Bisphosphonates in multiple myeloma: a network meta-analysis
    Rahul Mhaskar
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, USA
    Cochrane Database Syst Rev 5:CD003188. 2012
    ..This is an update of a Cochrane review first published in 2002 and previously updated in 2010...
  6. doi Sequence of novel agents in multiple myeloma: an instrumental variable analysis
    Rachid Baz
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Leuk Res 37:1077-82. 2013
    ..These findings were confirmed with instrumental variable analyses. Finally, use of bortezomib first was associated with improved survival for patients with baseline renal insufficiency. ..
  7. pmc Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials
    Benjamin Djulbegovic
    Center for Evidence based medicine and Health Outcomes Research, Tampa, Florida, USA
    PLoS ONE 8:e58711. 2013
    ..To assess if commercially sponsored trials are associated with higher success rates than publicly-sponsored trials...
  8. ncbi Management of multiple myeloma: a systematic review and critical appraisal of published studies
    Ambuj Kumar
    Interdisciplinary Oncology Program of the H Lee Moffitt Cancer and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Lancet Oncol 4:293-304. 2003
    ..We conclude that the quality of total evidence supporting treatment recommendations in myeloma is modest at best and has an ample scope for improvement...
  9. doi Towards a classification model to identify hospice candidates in terminally ill patients
    Eleazar Gil-Herrera
    Department of Industrial and Management System Engineering, University of South Florida, Tampa, FL 33620, USA
    Conf Proc IEEE Eng Med Biol Soc 2012:1278-81. 2012
    ..Retrospective data from 9105 patients is used to demonstrate the design and implementation details of the classification model...
  10. doi Optimal information size in trial sequential analysis of time-to-event outcomes reveals potentially inconclusive results because of the risk of random error
    Branko Miladinovic
    Center for Evidence based medicine and Health Outcomes Research, Department of Internal Medicine, Clinical and Translational Science Institute, Morsani College of Medicine, University of South Florida, 3515 East Fletcher Avenue, MDC 27, Tampa, FL 33612, USA
    J Clin Epidemiol 66:654-9. 2013
    ..We conducted a TSA for time-to-event outcomes and applied the method to determine the risk of random error in MAs for treatments of multiple myeloma...
  11. doi Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation
    Joseph Pidala
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9416, USA
    Biol Blood Marrow Transplant 15:1415-21. 2009
    ..PBSC is the optimal stem cell source in terms of both overall and quality-adjusted life expectancy, except in conditions with a very low relapse probability, in which BM provides optimal outcomes...
  12. pmc Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group
    Ambuj Kumar
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    BMJ 331:1295. 2005
    ....
  13. doi Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis
    Ambuj Kumar
    Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA
    J Natl Cancer Inst 101:100-6. 2009
    ..We performed a systematic review and meta-analysis to synthesize the existing evidence related to the effectiveness of tandem vs single AHCT in patients with MM...
  14. ncbi Erythropoietin use in oncology: a summary of the evidence and practice guidelines comparing efforts of the Cochrane Review group and Blue Cross/Blue Shield to set up the ASCO/ASH guidelines
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Best Pract Res Clin Haematol 18:455-66. 2005
    ..In this paper, the findings from the guidelines set by ASH/ASCO that were culled from systematic reviews by BCBSA TEC and the Cochrane Review are compared and contrasted...
  15. doi Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis
    Mohamed A Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Tampa, FL, USA Department of Oncologic Sciences, H Lee Moffitt Cancer Center University of South Florida College of Medicine, Tampa, FL, USA
    Br J Haematol 163:315-25. 2013
    ..Addition of GO to conventional chemotherapy as induction therapy may improve relapse-free and event-free survival, but does not impact overall survival and significantly increases early mortality in AML. ..
  16. pmc Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols
    Rahul Mhaskar
    Division and Center for Evidence Based Medicine and Outcomes Research, Department of Internal Medicine, Clinical and Translational Science Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA
    J Clin Epidemiol 65:602-9. 2012
    ..To assess whether the reported methodological quality of randomized controlled trials (RCTs) reflects the actual methodological quality and to evaluate the association of effect size (ES) and sample size with methodological quality...
  17. ncbi Bisphosphonates in multiple myeloma
    Rahul Mhaskar
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, USA
    Cochrane Database Syst Rev 3:CD003188. 2010
    ..Also, with the baseline risk of 35% to 86% for SREs without treatment, we estimate that between six and 15 MM patients should be treated to prevent SRE(s) in one patient. No bisphoshphonate appears to be superior to others...
  18. ncbi High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:183-96. 2007
    ..01; 95% confidence interval, 1.64-5.50). Hence, evaluating alternative therapeutic options upfront may also be reasonable...
  19. pmc Instrumental variable meta-analysis of individual patient data: application to adjust for treatment non-compliance
    Branko Miladinovic
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, FL, USA
    BMC Med Res Methodol 11:55. 2011
    ..Our objective is to correct for bias in non-experimental data from previously published individual patient data meta-analysis by applying IV methods..
  20. pmc Bad reporting does not mean bad methods for randomised trials: observational study of randomised controlled trials performed by the Radiation Therapy Oncology Group
    Heloisa P Soares
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    BMJ 328:22-4. 2004
    ..To determine whether poor reporting of methods in randomised controlled trials reflects on poor methods...
  21. doi Trial sequential analysis may be insufficient to draw firm conclusions regarding statistically significant treatment differences using observed intervention effects: a case study of meta-analyses of multiple myeloma trials
    Branko Miladinovic
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, FL, USA
    Contemp Clin Trials 34:257-61. 2013
    ..We recommend that the conclusion of significant treatment differences in cumulative MA should be weighed against acceptable thresholds regarding the type I error, power and apriori specified clinically meaningful treatment difference...
  22. ncbi Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?
    Mohamed A Kharfan-Dabaja
    Division of Blood and Marrow Transplantation, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Rsearch Institute, University of South Florida, Tampa, FL 33612, USA
    Br J Haematol 139:234-42. 2007
    ..It is uncertain whether autograft is superior to conventional therapy. The high incidence of myelodysplastic syndrome (9-12%) is particularly concerning in CLL, where median survival is 9 years...
  23. ncbi Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design
    Madhusmita Behera
    Malignant Hematology Program, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Control 14:160-6. 2007
    ..The randomized, controlled trial (RCT) is the "gold standard" for establishing the effect of any intervention. This approach, however, is often not feasible with rare diseases such as cutaneous T-cell lymphoma...
  24. ncbi A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer
    Tawee Tanvetyanon
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida 33612, USA
    J Thorac Oncol 2:1091-7. 2007
    ..We evaluated available literatures to summarize the state of current knowledge and provide suggestions for future studies...
  25. doi Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: a systematic review
    Rahul Mhaskar
    Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida 33612, USA
    Biol Blood Marrow Transplant 15:893-902. 2009
    ..But the quality of our evidence is low, indicating a need for well-designed and adequately powered RCTs to better address the role of AHCT in AL amyloidosis...
  26. ncbi External validation of a web-based prognostic tool for predicting survival for patients in hospice care
    Branko Miladinovic
    Center for Evidence based medicine and Health Outcomes Research, Morsani College of Medicine, University of South Florida, 3515 E Fletcher Avenue, MDT1200, Mail Code MDC27, Tampa, Florida 33612, USA
    J Palliat Care 29:140-6. 2013
    ..If it is to be useful to patients and clinicians, Prognostat needs to explicitly report patient risk scores and estimates of baseline survival...
  27. pmc Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
    Mohamed A Kharfan-Dabaja
    Blood and Marrow Transplantation Program, H Lee Moffitt Cancer Center University of South Florida College of Medicine, Tampa, FL, USA
    J Hematol Oncol 6:2. 2013
    ..A previously published meta-analysis has been reported; however, it suffers from serious methodological flaws...
  28. pmc Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis
    Hesborn Wao
    Center for Evidence Based Medicine and Outcomes Research, Department of Internal Medicine, Morsani College of Medicine, University of South Florida Clinical and Translational Science Institute, 3515 East Fletcher Avenue, MDT 1202, Tampa, FL, 33612, USA
    Syst Rev 2:10. 2013
    ..Specifically, we estimated overall survival when no anticancer therapy is provided...
  29. pmc A flexible alternative to the Cox proportional hazards model for assessing the prognostic accuracy of hospice patient survival
    Branko Miladinovic
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, USA
    PLoS ONE 7:e47804. 2012
    ..Researchers involved in prognosticating patient survival are encouraged to consider the Royston-Parmar model as an alternative to Cox...
  30. doi Rough Set Theory based prognostication of life expectancy for terminally ill patients
    Eleazar Gil-Herrera
    Department of Industrial and Management System Engineering, University of South Florida, Tampa, FL 33620, USA
    Conf Proc IEEE Eng Med Biol Soc 2011:6438-41. 2011
    ..Preliminary results confirm the efficacy of the proposed methodology. We envision our work as a part of a comprehensive decision support system designed to assist terminally ill patients in making end-of-life care decisions...
  31. pmc Extensions to regret-based decision curve analysis: an application to hospice referral for terminal patients
    Athanasios Tsalatsanis
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, FL, USA
    BMC Med Inform Decis Mak 11:77. 2011
    ..Decision systems to improve the hospice referral process are sorely needed...
  32. pmc Optimism bias leads to inconclusive results-an empirical study
    Benjamin Djulbegovic
    Department of Medicine, Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, FL 33612, USA
    J Clin Epidemiol 64:583-93. 2011
    ..We assessed the impact of optimism bias on a proportion of trials that did not answer their research question successfully and explored whether poor accrual or optimism bias is responsible for inconclusive results...
  33. ncbi What kind of evidence do patients and practitioners need: evidence profiles based on 5 key evidence-based principles to summarize data on benefits and harms
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Treat Rev 32:572-6. 2006
  34. ncbi Articulating and responding to uncertainties in clinical research
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, University of South Florida, Tampa, Florida 33612, USA
    J Med Philos 32:79-98. 2007
    ..That is, [acknowledgement of] uncertainty determines a pattern of success in medicine and drives clinical discoveries...
  35. ncbi Treatment tolerance and efficacy in geriatric oncology: a systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups
    Ambuj Kumar
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL 33612, USA
    J Clin Oncol 25:1272-6. 2007
    ..A systematic review to assess the accurate participation of elderly patients in RCTs has not been performed...
  36. doi Treatment of patients with multiple myeloma: an overview of systematic reviews
    Ambuj Kumar
    Center for Evidence based Medicine and Health Outcome Research, University of South Florida, USA
    Acta Haematol 125:8-22. 2011
    ..There is urgent need to perform research synthesis of data related to the effects of novel agents...
  37. pmc When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt
    Benjamin Djulbegovic
    Center for Evidence based Medicine and Health Outcome Research, Clinical Translational Science Institute and Department of Internal Medicine, University of South Florida, Tampa, FL, USA
    BMC Med Res Methodol 12:85. 2012
    ..This tension creates a key dilemma: when is it rational, from the perspective of the trial patients and researchers (as societal representatives of future patients), to enroll in RCTs?..
  38. pmc Dual processing model of medical decision-making
    Benjamin Djulbegovic
    Center for Evidence based medicine and Health Outcomes Research, Tampa, FL, USA
    BMC Med Inform Decis Mak 12:94. 2012
    ..Here we postulate such a model and apply it to a common clinical situation: whether treatment should be administered to the patient who may or may not have a disease...
  39. pmc A social network analysis of treatment discoveries in cancer
    Athanasios Tsalatsanis
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, Florida, United States of America
    PLoS ONE 6:e18060. 2011
    ..We conclude that the chances of discovering life-saving treatments are directly related to the richness of social interactions between researchers inherent in a preferential interaction model...
  40. ncbi Evidence profiles for colo-rectal cancer: benefit/harms data based on the totality of randomized evidence
    Ambuj Kumar
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Department of Interdisciplinary Oncology and Cancer Prevention and Control, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Treat Rev 32:577-80. 2006
  41. ncbi The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials
    Benjamin Djulbegovic
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Account Res 10:301-15. 2003
    ..We argue that an adequate control intervention can be selected if people designing a trial explicitly take into consideration the ethical principle of equipoise, also known as "the uncertainty principle."..
  42. doi Value of repeat head computed tomography after traumatic brain injury: systematic review and meta-analysis
    Tea Reljic
    1 Center for Evidence Based Medicine and Health Outcomes Research, University of South Florida, Tampa, Florida
    J Neurotrauma 31:78-98. 2014
    ..The evidence suggests that repeat CT in patients with TBI results in a change in management for only a minority of patients. Better designed studies are needed to address the issue of the value of repeat CT in the management of TBI. ..
  43. pmc A regret theory approach to decision curve analysis: a novel method for eliciting decision makers' preferences and decision-making
    Athanasios Tsalatsanis
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, FL, USA
    BMC Med Inform Decis Mak 10:51. 2010
    ..We use the cognitive emotion of regret to serve as a link between systems 1 and 2 and to reformulate DCA...
  44. doi Designing patient-centric applications for chronic disease management
    Athanasios Tsalatsanis
    Center for Evidence based medicine and Health Outcomes Research, University of South Florida, Tampa, FL 33612, USA
    Conf Proc IEEE Eng Med Biol Soc 2011:3146-9. 2011
    ..We also outline preliminary results regarding a self-management application currently under development targeting young adults suffering from type 1 diabetes...
  45. ncbi Evidence-based oncology in cancer treatment reviews
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center, Florida, USA
    Cancer Treat Rev 29:45-50. 2003
  46. ncbi Epistemologic inquiries in evidence-based medicine
    Benjamin Djulbegovic
    Center for Evidence Based Medicine and Health Outcomes Research and the Clinical Translational Science Institute at the University of South Florida, Tampa, Florida 33612, USA
    Cancer Control 16:158-68. 2009
    ..Undertaking epistemological inquiry is important because the adoption of a particular epistemological view defines how science is conducted...
  47. ncbi Management of venous Thromboembolism in cancer: a brief review of risk-benefit approaches and guidelines' recommendations
    Benjamin Djulbegovic
    Medicine and Oncology, University of South Florida, Tampa, FL 33612, USA
    J Support Oncol 8:84-91. 2010
    ..Hence, there is an urgent need to develop a clinical decision-support system that can help integrate benefits and risks as well as take into account patients' preferences and values in managing VTE...
  48. ncbi Evidence and decision making. Commentary on M.R. Tonelli (2006), Integrating evidence into clinical practice: an alternative approach to evidence-based approaches. Journal of Evaluation in Clinical Practice 12, 248-256
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Department of Interdisciplinary Oncology, Tampa, FL, USA
    J Eval Clin Pract 12:257-9. 2006
  49. ncbi Evidence-based oncology section - aims and scope
    Benjamin Djulbegovic
    H Moffit Cancer Centre, Florida, USA
    Cancer Treat Rev 29:51-3. 2003
  50. ncbi Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission
    Joseph Pidala
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Division of Oncologic Sciences, University of South Florida, Tampa, Florida, USA
    Cochrane Database Syst Rev 10:CD008818. 2011
    ....
  51. pmc Uncertainty and equipoise: at interplay between epistemology, decision making and ethics
    Benjamin Djulbegovic
    Center and Division for Evidence based Medicine and Health Outcome Research, Clinical Translational Science Institute, University of South Florida, Tampa, Florida, USA
    Am J Med Sci 342:282-9. 2011
    ..Ultimately, our choices can only become wiser if we understand a close and intertwined relationship between irreducible uncertainty, inevitable errors and unavoidable injustice...
  52. ncbi Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
    Melissa Alsina
    Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute and Department of Oncology, University of South Florida, Tampa, FL 33612, USA
    Blood 103:3271-7. 2004
    ..We conclude that tipifarnib is tolerable, can induce disease stabilization, and can inhibit farnesylation and oncogenic/tumor survival pathways...
  53. ncbi Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review
    Benjamin Djulbegovic
    Malignant Hematology Program, H Lee Moffitt Cancer Center Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Cancer Control 10:17-41. 2003
    ..They hypothesize that NM-allo-SCT is equally efficacious to standard allo-SCT but produces less regimen-related toxicity...
  54. ncbi Why evidence based oncology management
    Ambuj Kumar
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    J Oncol Manag 11:13-6. 2002
  55. doi Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis
    Mohamed A Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, Florida, USA
    Biol Blood Marrow Transplant 15:1005-13. 2009
    ....
  56. ncbi Screening mammography at 40-49 years: regret or no regret?
    Benjamin Djulbegovic
    H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Department of Interdisciplinary Oncology, Tampa, FL 33612, USA
    Lancet 368:2035-7. 2006
  57. pmc Erythropoietin, uncertainty principle and cancer related anaemia
    Otavio Clark
    Interdisciplinary Oncology Program H, Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa, FL, USA
    BMC Cancer 2:23. 2002
    ..We also wanted to demonstrate that cumulative meta-analysis (CMA) can be used to resolve uncertainty regarding clinical questions...
  58. pmc The paradox of equipoise: the principle that drives and limits therapeutic discoveries in clinical research
    Benjamin Djulbegovic
    Center for Evidence Based Medicine and Health Outcomes Research and the Clinical Translational Science Institute, The University of South Florida, Tampa, Florida 33612, USA
    Cancer Control 16:342-7. 2009
    ..This guarantee is provided by the acknowledgment of uncertainty (equipoise), which removes ethical dilemmas and makes it easier for patients to enroll in clinical trials...
  59. pmc Impact of quality of evidence on the strength of recommendations: an empirical study
    Benjamin Djulbegovic
    Center for Evidence based Medicine and Health Outcome Research, Clinical Translational Science Institute, Florida, USA
    BMC Health Serv Res 9:120. 2009
    ..Surprisingly, and despite the widespread penetration of EBM in health care, there has been no empirical research to date investigating the impact of quality of evidence on the strength of recommendations made by guidelines panels...
  60. ncbi Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?
    Andrew Bottomley
    Quality of Life Unit, EORTC Data Center, Brussels, Belgium
    Lancet Oncol 3:145-53. 2002
    ..Evidence from this review suggests that more robust designs are required to show any significant quality-of-life benefits for cancer patients undergoing epoetin treatment...
  61. ncbi Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI 53226, USA
    Blood 100:2303-20. 2002
    ..Therefore, for anemic patients with hematologic malignancies it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin...
  62. ncbi The challenge of systematic reviews of diagnostic and staging studies in cancer
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Cancer Treat Rev 31:628-39. 2005
    ..However, controversy remains as to which outcomes to measure and when long term outcomes based on large and costly randomized trials are required...
  63. ncbi Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients
    Julia Bohlius
    Department of Internal Medicine I, University of Cologne, Germany
    J Natl Cancer Inst 98:708-14. 2006
    ..08, 95% CI = 0.99 to 1.18; 42 trials and 8167 patients). Caution is advised when using epoetin or darbepoetin in combination with thrombogenic chemotherapeutic agents or for cancer patients who are at high risk for thrombo-embolic events...
  64. ncbi Systematic review of piperacillin-induced neutropenia
    Marc H Scheetz
    Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL 60611, USA
    Drug Saf 30:295-306. 2007
    ..Report of neutropenia associated with piperacillin usage prior to 15 days of therapy is a novel finding that requires further evaluation. Current reporting methods poorly characterise patient groups at risk...
  65. ncbi High-quality evidence in oncology from 18th May to 15th June 2004: a summary
    Benjamin Djulbegovic
    Bazian Ltd, 138 Upper Street, Suites 1 and 2, London N1 1QP, UK
    Cancer Treat Rev 30:721-3. 2004
  66. ncbi High-quality evidence in oncology from 20th April to 11th May 2004: a summary
    Benjamin Djulbegovic
    Cancer Treat Rev 30:665-7. 2004
  67. ncbi High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis
    John Strehl
    Medizinische Klinik und Poliklinik I der Rheinischen Friedrich Wilhelms Universit├Ąt Bonn, Germany
    Haematologica 88:1304-15. 2003
    ..Therefore, HDT/ASCT was evaluated as part of first-line therapy. Several trials generated conflicting results. This meta-analysis summarizes the available evidence from all suitable studies...
  68. ncbi A systematic review and lessons learned from early lung cancer detection trials using low-dose computed tomography of the chest
    Gerold Bepler
    Thoracic Oncology Program, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
    Cancer Control 10:306-14. 2003
    ..Computed tomography (CT) screening of the chest has shown promise for early detection of lung cancer, but evidence for a reduction in lung cancer mortality by CT screening is not available...
  69. pmc Pharmaceutical industry sponsorship and research outcome and quality: systematic review
    Joel Lexchin
    School of Health Policy and Management, York University, Toronto, ON, Canada M3J 1P3
    BMJ 326:1167-70. 2003
    ....
  70. ncbi Failure of equipoise to resolve the ethical tension in a randomized clinical trial
    Howard Mann
    J Law Med Ethics 31:5-6. 2003
  71. ncbi Off-study availability of investigational treatments
    Howard Mann
    Lancet 361:1302. 2003
  72. ncbi Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Oncol 20:4083-107. 2002
    ..Therefore, for anemic patients with hematologic malignancies, it is recommended that physicians initiate conventional therapy and observe hematologic response before considering use of epoetin...
  73. ncbi Erythropoietin improves quality of life--a response
    Andrew Bottomley
    Quality of Life Unit, EORTC Data Center, Brussels, Belgium
    Lancet Oncol 3:527. 2002
  74. ncbi At what degree of belief in a research hypothesis is a trial in humans justified?
    Benjamin Djulbegovic
    Interdisciplinary Oncology Programme, H Lee Moffitt Cancer Center and Research Institute at the University of South Florida, Tampa 33612, USA
    J Eval Clin Pract 8:269-76. 2002
    ..The purpose of this study is to determine the degree of uncertainty in a research hypothesis before it can empirically be tested in an RCT...
  75. ncbi Priority-setting decisions for new cancer drugs
    Keith Wheatley
    Lancet 359:1525. 2002
  76. pmc Evaluation of new treatments in radiation oncology: are they better than standard treatments?
    Heloisa P Soares
    H Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa 33612, USA
    JAMA 293:970-8. 2005
    ..To describe accurately the outcomes of innovations that are tested in randomized controlled trials (RCTs) 3 factors have to be considered: publication rate, quality of trials, and the choice of the adequate comparator intervention...
  77. pmc Estimating the mean and variance from the median, range, and the size of a sample
    Stela Pudar Hozo
    Department of Mathematics, Indiana University Northwest, Gary, IN 46408, USA
    BMC Med Res Methodol 5:13. 2005
    ..However, sometimes the published reports of clinical trials only report the median, range and the size of the trial...
  78. ncbi High-quality evidence in oncology from 1st September to 14th October 2004: a summary
    Benjamin Djulbegovic
    Cancer Treat Rev 31:155-7. 2005
  79. ncbi Cancer- and chemotherapy-induced anemia
    George M Rodgers
    Huntsman Cancer Institute, University of Utah, Utah, USA
    J Natl Compr Canc Netw 6:536-64. 2008
  80. doi Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
    Charles L Bennett
    VA Chicago Healthcare System, Department of Medicine, Northwestern University Feinberg School of Medicine, and Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois 60611, USA
    JAMA 299:914-24. 2008
    ..Although systematic overviews of trials have identified venous thromboembolism (VTE) risks, none have identified mortality risks with ESAs...
  81. doi Recommendations on the use of 18F-FDG PET in oncology
    James W Fletcher
    Department of Radiology, Indiana Purdue University, Indiana University School of Medicine, Indianapolis, Indiana 46202 5253, USA
    J Nucl Med 49:480-508. 2008
    ..Outcomes of interest included the use of (18)F-FDG PET for diagnosing, staging, and detecting the recurrence or progression of cancer...
  82. ncbi Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    J Clin Oncol 26:132-49. 2008
    ..The guideline was expanded to address use of darbepoetin and thromboembolic risk associated with these agents...
  83. ncbi Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update
    J Douglas Rizzo
    Medical College of Wisconsin, Milwaukee, WI, USA
    Blood 111:25-41. 2008
    ..The guideline was expanded to address use of darbepoetin and thromboembolic risk associated with these agents...
  84. ncbi Multiple myeloma. Clinical practice guidelines in oncology
    Kenneth C Anderson
    J Natl Compr Canc Netw 5:118-47. 2007
  85. ncbi Cancer treatment reviews welcomes submission of the Cochrane Reviews
    Nicholas Pavlidis
    Cancer Treat Rev 32:243-4. 2006
  86. ncbi High-quality evidence in oncology from 25 August to 27 October 2005: A summary
    Benjamin Djulbegovic
    Evidence based Oncology section
    Cancer Treat Rev 32:149-55. 2006
  87. ncbi Cancer- and treatment-related anemia
    George M Rodgers
    J Natl Compr Canc Netw 3:772-89. 2005
  88. ncbi Oncology treatment recommendations can be supported only by 1-2% of high-quality published evidence
    Sam Vincent
    Cancer Treat Rev 31:319-22. 2005
  89. ncbi Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials
    Otavio A C Clark
    Hospital Celso Pierro PUC Campinas, Sao Paulo, Brazil
    J Clin Oncol 23:4198-214. 2005
    ..This Cochrane Collaboration review was undertaken to further evaluate the safety and efficacy of the CSFs in patients with FN...
  90. pmc Use of re-randomized data in meta-analysis
    Iztok Hozo
    Department of Mathematics, Indiana University Northwest, Gary, IN, USA
    BMC Med Res Methodol 5:17. 2005
    ..The probability of an event is not always the same when a patient is re-randomized; there is probably a non-zero covariance coming from observations on the same patient. This is of particular importance to the meta-analysts...
  91. ncbi Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis
    Gary H Lyman
    Center for Health Outcomes and PharmacoEconomic Research, Albany Medical College, State University of New York, Albany, NY, USA
    Am J Med 112:406-11. 2002
    ..We performed a meta-analysis to define better the magnitude of this effect and to assess the generalizability of the results among different diseases and types of treatment...

Research Grants7

  1. Equipoise and the research integrity of clinical trials
    Benjamin Djulbegovic; Fiscal Year: 2002
    ..This proposal will answer both the question "what do trials do for us?" and assess the reliability of the research in which public has invested so much. ..
  2. Blood vs. bone marrow stem transplant
    Benjamin Djulbegovic; Fiscal Year: 2003
    ..We will test all these hypotheses by collecting individual-patient data on each outcomes of interest from the existing data sets (i.e. from published and unpublished randomized studies) using the techniques of SR/MA. ..
  3. Evaluation of the Quality of Clinical Trials
    Benjamin Djulbegovic; Fiscal Year: 2005
    ..It is also hoped that public confidence in COG research may further increase, which in turn will enable development of more rapid advances in the war against cancer. ..
  4. Treatment Success and Ethical Principle of Equipoise
    Benjamin Djulbegovic; Fiscal Year: 2010
    ..abstract_text> ..